Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I see Leo is laser-focused on B-OM again.

The Company is presently exploring timelines and scenario planning—including the option to seek a meeting with the U.S. Food and Drug Administration towards the initiation of a Phase 3 clinical trial evaluating oral rinse Brilacidin as a new treatment for the prevention of OM in head and neck cancer patients receiving chemoradiation.

https://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases

Leo, you did that more than three years ago.

Both parties agreed to an acceptable Brilacidin Phase 3 development pathway, including studying Brilacidin oral rinse effects on SOM when cisplatin is administered in higher concentrations (80-100 mg/m2) every 21 days, and at lower concentrations (30-40 mg/m2) administered weekly as part of the chemoradiation regimen.

https://www.ipharminc.com/press-release/2018/12/17/innovation-pharmaceuticals-completes-end-of-phase-2-meeting-with-fda-brilacidin-oral-rinse-to-advance-into-phase-3-clinical-trials-for-prevention-of-severe-oral-mucositis